Neuronuclear imaging in the evaluation of dementia and mild decline in cognition

Seminars in Nuclear Medicine

Volumn 42, Issue 6, 2012, Pages 415-422

  Torosyan, Nare ^a   Silverman, Daniel H S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE;

ALZHEIMER DISEASE; ARTICLE; BRAIN TISSUE; CEREBROSPINAL FLUID; COGNITION; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; HUMAN; MENTAL DETERIORATION; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT INDICATION;

EID: 84869066515     PISSN: 00012998     EISSN: 15584623     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2012.06.004     Document Type: Review

References (40)

1. Gauthier S, Reisberg B, Zaudig M, et al: Mild cognitive impairment. Lancet 2006;367:1262-1270
2. Brookmeyer R, Johnson E, Ziegler-Graham K, et al: Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 2007;3:186- 191
3. Alzheimer's Association: 2012 Alzheimer's disease facts and figures. Alzheimers Dement 2012;8:131-168
4. Hebert LE, Scherr PA, Bienias JL, et al: Alzheimer disease in the US population: Prevalence estimates using the 2000 census. Arch Neurol 2003;60:1119-1122
5. Sloane PD, Zimmerman S, Suchindran C, et al: The public health impact of Alzheimer's disease, 2000-2050: Potential implication of treatment advances. Annu Rev Public Health 2002;23:213-231
6. Lindsay J, Laurin D, Verreault R, et al: Risk factors for Alzheimer's disease: A prospective analysis from the Canadian study of health and aging. Am J Epidemiol 2002;156:445-453
7. Saczynski JS, Beiser A, Seshadri S, et al: Depressive symptoms and risk of dementia: The Framingham heart study. Neurology 2010;75:35-41
8. Cummings JL. Alzheimer's disease. N Engl J Med 2004;351:56-67
9. Petersen RC, Doody R, Kurz A, et al: Current concepts in mild cognitive impairment. Arch Neurol 2001;58:1985-1992
10. Silverman DH, Mosconi L, Ercoli L, et al: Positron emission tomography scans obtained for the evaluation of cognitive dysfunction. Semin Nucl Med 2008;38:251-261
11. Landau SM, Harvey D, Madison CM, et al: Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging 2011;32:1207-1218
12. Toney LK, McCue TJ, Minoshima S, et al: Nuclear medicine imaging in dementia: A practical overview for hospitalists. Hosp Prac (Minneap) 2011;39:149-160
13. Diagnostic and Statistical Manual of Mental Disorders, Text Revision: DSM-IV-TR (ed 4). Washington, DC, American Psychiatric Association, 2000
14. Neurocognitive Disorders. American Psychiatric Association 2012. Available on: http://www.dsm5.org/proposedrevision/pages/ neurocognitivedisorders.aspx. Accessed March 30, 2012. Accessed March 30, 2012
15. Albert MS, DeKosky ST, Dickson D, et al: The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:270-279
16. Hort J, O'Brien JT, Gainotti G, et al: EFNS guidelines for the diagnosis and management of Alzheimer's disease. Eur J Neurol 2010;17:1236- 1248
17. Hort J, Bartos A, Pirttilä T, et al: Use of cerebrospinal fluid biomarkers in diagnosis of dementia across Europe. Eur J Neurol 2010;17:90-96
18. Desikan RS, Cabral HJ, Hess CP, et al: Automated MRI measures identify individuals with mild cognitive impairment and Alzheimer's disease. Brain 2009;132:2048-2057
19. Desikan RS, Cabral HJ, Settecase F, et al: Automated MRI measures predict progression to Alzheimer's disease. Neurobiol Aging 2010;31: 1364-1374
20. Herholz K. Perfusion SPECT and FDG-PET. Int Psychogeriatr 2011; 23(suppl 2):S25-S31
21. Farid K, Caillat-Vigneron N, Sibon I: Is brain SPECT useful in degenerative dementia diagnosis? J Comput Assist Tomogr 2011;35:1-3
22. Heertum RV, Tikofsky R, Ruben A: Functional Cerebral SPECT and PET Imaging (ed 3). New York, Lippincott Williams and Wilkins, 2000
23. Minoshima S, Giordano B, Berent S, et al: Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 1997;42:85-94
24. Mosconi L: Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging 2005;32:486-510
25. Bohnen NI, Djang DS, Herholz K, et al: Effectiveness and safety of 18F-FDG PET in the evaluation of dementia: A review of the recent literature. J Nucl Med 2012;53:59-71
26. Silverman DHS, Small GW, Chang CY, et al: Positron emission tomography in evaluation of dementia. JAMA 2001;286:2120-2127
27. Jagust W, Reed B, Mungas D, et al: What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? Neurology 2007;69: 871-877
28. Mosconi L, Sorbi S, de Leon MJ, et al: Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease. Journal of nuclear medicine: official publication, Society of Nuclear Medicine 2006;47(11):1778- 1786
29. Dougall NJ, Bruggink S, Ebmeier KP: Systematic review of the diagnostic accuracy of 99mTc-HMPAO-SPECT in dementia. Am J Geriatr Psychiatry 2004;12:554-570
30. Colloby SJ, Firbank MJ, Pakrasi S, et al: A comparison of 99mTcexametazime and 123I-FP-CIT SPECT imaging in the differential diagnosis of Alzheimer's disease and dementia with Lewy bodies. Int Psychogeriatr 2008;20:1124-1140
31. Foster NL, Heidebrink JL, Clark CM, et al: FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain 2007;130:2616-2635
32. Berti V, Pupi A, Mosconi L: PET/CT in diagnosis of dementia. Ann N Y Acad Sci 2011;1228:81-92
33. Moghbel MC, Saboury B, Basu S, et al: Amyloid-imaging with PET in Alzheimer's disease: Is it feasible with current radiotracers and technologies? Eur J Nucl Med Mol Imaging 2012;39:202-208
34. Clark CM, Schneider JA, Bedell BJ, et al: Use of florbetapir-PET for imaging -amyloid pathology. JAMA 2011;305:275-283
35. Bennett DA, Cochran EJ, Saper CB, et al: Pathological changes in frontal cortex from biopsy to autopsy in Alzheimer's disease. Neurobiol Aging 1993;14(6):589-596
36. Quigley H, Colloby SJ, O'Brien JT: PET imaging of brain amyloid in dementia: A review. Int J Geriatr Psychiatry 2011;26:991-999
37. Silverman DHS. Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: Comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging. J Nucl Med 2004;45:594-607
38. Silverman DH: PET in the Evaluation of Alzheimer's Disease and Related Disorders. New York, Springer Science-Business Media, 2009, pp 41-45
39. Silverman DH, Geist CL, Kenna HA, et al: Differences in regional brain metabolism associated with specific formulations of hormone therapy in postmenopausal women at risk for AD. Psychoneuroendocrinology 2011;36:502-513
40. Silverman DHS, Gambhir SS, Huang H-WC, et al: Evaluating Early Dementia With and Without Assessment of Regional Cerebral Metabolism by PET: A Comparison of Predicted Costs and Benefits. Journal of Nuclear Medicine 2002;43(2):253-266